With over three decades of experience, Central Florida Retina is proud
to be leading the way in the latest and most innovative treatments of retina and vitreous diseases.
CLINICAL TRIALS & YOU
1 | What is A Clinical Trial?
A clinical trial is a research study in human volunteers to answer specific health questions. Carefully conducted clinical trials are the safest and fastest way to find treatments that work in people and new ways to improve health.
2 | Who Should Consider Clinical Trials?
Some people participate in clinical trials because they have exhausted standard (approved) treatment options. These options either did not work for them or they were unable to tolerate certain side effects. Clinical trials may provide another option when standard therapy has failed.
3 | How is a Clinical Trial Conducted?
An agreement form is provided to you and explains what the study involves. It is also reviewed with you by members of the research department. Being in a study is completely voluntary, and you can change your mind at any time even if you have already signed the consent form.
Central Florida Retina is currently enrolling patients who are interested in participating in one of the following studies.
1 | FOR PATIENTS WHO HAVE BEEN DIAGNOSED WITH DIABETIC RETINOPATHY
The primary objective of the study is to assess the efficacy of intravitreal (IVT) aflibercept compared to sham treatment in the improvement of moderately severe to severe nonproliferative diabetic retinopathy (NPDR).
2 | FOR PATIENTS WHO HAVE BEEN DIAGNOSED WITH ALZHEIMER'S DISEASE
Phase 2/3 study to examine and test for retinal effects and visual changes while being administered disease specific study drug for dementia.
3 | GENETIC STUDIES
Study designed to observe and identify the risk factors that contribute to genetic Age Related Macular Degeneration.
Study designed to assist in Blood/DNA collection for the National Ophthalmic Disease Genotyping and Phenotyping Network.
CONTACT THE RESEARCH DEPT
For more info or to learn about how to enroll in one of our current studies, please fill out the form below. Thank you!
CFR Research Department
PAST CLINICAL TRIALS
1 | WET AGE-RELATED MACULAR DEGENERATION
A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration
A Phase III study randomized, parallel-group, multicenter, double-masked study of the safety and efficacy of Anecortave Acetate for Depot Suspension (15mg and 30 mg) versus sham administration in arresting the progression of non-exudative (dry) AMD in patients who are at risk for progressing to exudative (wet) AMD.
A Phase I Single Ascending Dose Trial To Establish The Safety, Tolerability And Pharmacokinetic Profile Of Intravitreous Injections Of E10030 (Anti-Pdgf Pegylated Aptamer) Monotherapy And Of E10030 Given In Combination With Lucentis 0.5mg/Eye In Subjects With Neovascular Age-Related Macular Degeneration
A Phase II Multicenter, Randomized, Double-Masked, Placebo Controlled, Dose- Comparison Study of the Safety and Efficacy of Fenretinide in the Treatment of Geographic Atrophy in Subjects With Age-Related Macular Degeneration
Genentech & Novartis SAILOR
A Phase IIIB, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
A Phase II/III Multi-Center, Randomized, Clinical Trial to evaluate the Effects of Preservative-Free Triamcinolone Acetonide as an Adjunct to Photodynamic Therapy in Participants with neovascular Age-Related Macular Degeneration (AMD)
A Phase IIIstudy which compares efficacy of subjects who have Lucentis®, injected into the eye once a month for two years, to PDT (Visudyne®), administered to the eye every three months for two years. in patients with wetAge-related Macular Degeneration (AMD)
Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion
2 | DIABETIC MACULAR EDEMA
A Randomized, Double-Masked, Parallel Group, Multi-Center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5 μg/day and ASI-001B 0.2 μg/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema
A Phase II study for evaluation of Anti-VEGF therapy, Bevacizumab (Avastin) Intravitreal injections in Subjects with Diabetic Macular Edema